Rhythm Pharmaceuticals, Inc. (RYTM) income statement
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30268% above fair value
$119.04+2.43 (+2.08%)
Close on Nov 18, 2026Market cap $8.20BP/E –Yield –
Rhythm Pharmaceuticals, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 89.0%
- Operating margin
- -83.6%
- Net margin
- -85.6%
- Return on equity, FY2025
- -244.5%
Financial strength
- Current ratio
- 3.45
- Debt to equity
- 1.03
- Debt to assets
- 24.3%
- Cash to current liabilities
- 53.1%
Valuation
- P/E ratio
- –
- Price to sales
- 34.16
- Price to book
- 79.59
- Dividend yield
- –
See a number that looks wrong?